Enhancing the Response Rate to Recombinant Uricases in Patients with Gout
Naomi Schlesinger1, Lissa Padnick-Silver2, Brian LaMoreaux3
1Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Abstract:
Refractory, or uncontrolled, gout is a chronic, progressive, inflammatory arthropathy resulting from continued urate deposition after failed attempts to lower serum uric acid below the therapeutic threshold with oral urate-lowering therapies such as allopurinol and febuxostat. Recombinant uricase is increasingly being used to treat refractory gout; however, the immunogenicity of uricase-based therapies has limited the use of these biologic therapies. Antidrug antibodies against biologic therapies, including uricase and PEGylated uricase, can lead to loss of urate-lowering response, increased risk of infusion reactions, and subsequent treatment failure. However, co-therapy with an immunomodulator can attenuate antidrug antibody development, potentially increasing the likelihood of sustained urate lowering, therapy course completion, and successful treatment outcomes. This review summarizes evidence surrounding the use of immunomodulation as co-therapy with recombinant uricases.
Related Concept Videos
Urinary Tract Calculi III: Medical Management
Phase II Reactions: Glucuronidation
Drug Metabolism: Phase II Reactions
Antihypertensive Drugs: Action of Diuretics
Drug Elimination by Renal Route: Tubular Secretion
Renal Drug Excretion: Tubular Secretion
![Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F61682.jpg&w=3840&q=50)

